Published in Medicine and Law Weekly, October 13th, 2006
Pharmaprojects reports just three glitazars still in ongoing clinical trials, calling into question the validity of this class of drug for the treatment of diabetes. Furthermore, an examination of Pharmaprojects' extensive data for drugs acting on the same molecular targets indicates a similar trend, with seven discontinuations, one project suspension and no...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.